No matches

4 search results for: eosinophils

<b>Eosinophils</b> as a Biomarker for Type 2 Asthma

Pulmonology

Eosinophils as a Biomarker for Type 2 Asthma

15 min

expert video

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.

Pulmonology

ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

21 min

Podcast

Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.

Pulmonology

The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers

4 min

videoanimation

Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.

Pulmonology

Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

2 min

Infographic

This infographic explores the emerging concepts of disease activity, disease stability, and disease control in COPD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region